Learn more at www.euromyositis.eu, or contact Dr. Lundberg via email at [email protected] or Hector Chinoy, PhD, FRCP, BMBS, MSc, BMedSci, at [email protected].
Related Articles
New Tools for Myositis Diagnosis, Classification & Management
CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…
Myositis Mysteries
Why isn’t my myositis patient getting better?
Autoantibodies in Autoimmune Myopathy
In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical phenotypes in IIMs. Scientists continue to learn more about how these autoantibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…
A World of Difference: Updates from the Global Rheumatology Summit
The second annual Global Rheumatology Summit focused on climate change, conflict and migration, as well as other global issues in rheumatology.